About 200 reports
Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis
The innovative biologic therapies and their biosimilar counterparts hold promise for patients suffering from chronic diseases.
- 2.8 Allergy Immunotherapy: An Overview
There are two phases: Allergy Shots ##. ## Allergy Immunotherapy: An Overview Immunotherapy or biologic therapy, is a therapy that is designed to boost the body" s natural defenses to fight the disease/ allergy.
Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market
Chemotherapy may be used alone or with RT or a biological therapy.
Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19
Biologics: Targets and Therapy; ##(##): ##-##.
- Immunotherapy Drugs Sales Volume
Shenzhen Kangtai Biological Products Co., Ltd. is the biggest cancer vaccines producer in China.
This rapidly growing sector offers a number of opportunities to both biotechnology and pharmaceutical companies seeking to diversify away from traditional pharmacological compositions and towards a more therapeutic approach, similar to the successful arrival of targeted biologic
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
- 4.3 Pipeline Distribution by Mechanism of Action
Although the market for RA is crowded with multiple effective biologic therapies, it lacks curative treatments.
Global Regenerative Medicines Market - Size, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2015 - 2022
Regenerative Medicine Market Analysis by Technology On the basis of technology used, this market is segmented into small molecules & amp; biologics, gene therapy and cell therapy.
- PROVIDES A SWOT ANALYSIS OF OTHER BIOLOGIC THERAPIES (CAMPATH/LEMTRADA...
- EFFICACY OF OTHER BIOLOGIC THERAPIES (CAMPATH/LEMTRADA AND RITUXAN)...
Gene therapies segment is expected to be the fastest emerging technology due to tremendous potential of gene therapy in minimizing immune rejections, which commonly occur after transplantations.
Regenerative Medicine Market by technology, Material and Application - Global Opportunity Analysis and Industry Forecasts, 2014 - 2022
Based on product type, it is categorized into cell therapy, gene therapy, tissue engineering, and small molecules & amp; biologics.
THIS ALLIANCE WAS FORMED ON A PRIOR AGREEMENT BETWEEN WUXI BIOLOGICS AND MEDIMMUNE ON THE DEVELOPMENT AND COMMERCIALIZATION OF MEDI##, A NOVEL BIOLOGIC DEVELOPED FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES.
- IMCGP100: CURRENT STATUS OF DEVELOPMENT
- highlights the forecasted growth of the overall CAR-T cells market spanning
NOVEL TREATMENTS FORM ANOTHER ARM OF THE AVAILABLE THERAPIES WHICH INCLUDES THE BIOLOGIC THERAPY.
The company mainly focuses on various health solutions such as prescription medicines, vaccines, biologic therapies, animal health and biologic products worldwide.
- BIMEKIZUMAB - DRUG PROFILE
Using a Bayesian statistical analysis, there was high posterior probability (##%) that the ACR## RR of bimekizumab at Week ## was greater than those reported for current standard of care biologic treatments, including anti-IL-##A therapies.
Single-use Bioreactor Market by Product, Cell, Technology, Application, End User - Global Forecast to 2021
- GEOGRAPHICAL SNAPSHOT: SINGLE-USE BIOREACTORS MARKET
Bioproduction includes the manufacturing of therapeutic drugs based on biologics such as protein-based therapeutics, vaccines, gene therapies, and cell therapies.
- BRISTOL-MYERS SQUIBB (U.S.)
ENDOTOXIN TESTING IS USED IN CELL THERAPY, MONOCLONAL ANTIBODY TESTING, VACCINE TESTING, GENE THERAPY, AND DRUG DEVELOPMENT.
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016
These will be the first ever adequately powered long-term head-to-head studies with biologic medicines to differentiate the effectiveness of treatment in these conditions.